var data={"title":"Phentolamine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Phentolamine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6767?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=phentolamine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Phentolamine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=phentolamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Phentolamine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45617054\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>OraVerse</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209218\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>OraVerse;</li>\n      <li>Rogitine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209245\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Alpha <sub>1</sub> Blocker;</li>\n      <li>\n        Antidote, Extravasation;</li>\n      <li>\n        Antihypertensive</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209222\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation of norepinephrine, management (manufacturer&rsquo;s labeling):</b> Local infiltration: Inject 5 to 10 mg (diluted in 10 mL 0.9% sodium chloride) into extravasation area (as soon as possible after extravasation is noted but within 12 hours of extravasation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extravasation of other sympathomimetic vasopressors, management (off-label use):</i> Infiltrate extravasation site with 5 to 10 mg diluted in 10 to 20 mL 0.9% sodium chloride as soon as possible after extravasation; may readminister if patient remains symptomatic (Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnosis of pheochromocytoma (phentolamine-blocking test):</b> <b>Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis: IM, IV: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertensive episodes associated with pheochromocytoma, prevention and management:</b> <b>Note:</b> In the perioperative period, the use of other agents may be preferred due to slow onset of action and prolonged duration of phentolamine in comparison to the other agents (eg, nitroprusside) (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Preoperative:</i> IM, IV: 5 mg given 1 to 2 hours before surgery and repeat if needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intraoperative:</i> IV: Administer 5 mg as indicated to prevent or control paroxysms of hypertension, tachycardia, respiratory depression, seizure, or other effects associated with epinephrine intoxication resulting from tumor manipulation or other stressor (eg, intubation) (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertensive crisis (off-label use):</b> <b>Note:</b> Generally used in the setting of catecholamine excess (eg, pheochromocytoma) (Marik 2007): IV: 1 to 5 mg bolus; maximum single dose: 15 mg. A continuous infusion may be administered after initial bolus dosing (eg, 1 mg/hour titrated to blood pressure response) to a maximum infusion rate of 40 mg/hour (McMillian 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse):</b> Infiltration or block technique: Submucosal oral injection: <b>Note:</b> Dose is based upon the number of cartridges of local anesthetic administered. Infiltration or block injection:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.1 mg if one-quarter cartridge of anesthesia was administered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.2 mg if one-half cartridge of anesthesia was administered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.4 mg if 1 cartridge of anesthesia was administered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.8 mg if 2 cartridges of anesthesia were administered</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209233\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=phentolamine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Phentolamine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation of sympathomimetic vasopressors, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: <i>Norepinephrine extravasation:</i> Children and Adolescents: Local infiltration: Infiltrate area of extravasation with a small amount of a 0.5 to 1 mg/mL solution as soon as extravasation is noted but within 12 hours of extravasation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: <i>Extravasation of dopamine, epinephrine, norepinephrine, phenylephrine:</i> Limited data available: Infants, Children, and Adolescents: SubQ: Infiltrate area of extravasation with a small amount (eg, 1 mL given in 0.2 mL aliquots) of a 0.5 to 1 mg/mL solution within 12 hours of extravasation (Flemmer 1993; Hill 1991; MacCara 1983; Montgomery 1999). Total dose required depends on the size of extravasation; dose may be repeated if required. When reported, the total dose needed was 1 to 5 mL of a 1 mg/mL solution; however, other concentrations could be used (Montgomery 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnosis of pheochromocytoma (phentolamine blocking test): Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: Limited data available: Children and Adolescents: IV: 0.05 to 0.1 mg/kg/dose, maximum single dose: 5 mg (Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertensive episodes associated with pheochromocytoma, prevention and treatment: Note:</b> In the perioperative period, the use of other agents may be preferred due to slow onset of action and prolonged duration of phentolamine in comparison to the other agents (eg, nitroprusside) (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Preoperative:</i> Children and Adolescents: IM, IV: 1 mg given 1 to 2 hours before surgery and repeat if needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intraoperative:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children and Adolescents: IV: 1 mg as indicated to prevent or control paroxysms of hypertension, tachycardia, respiratory depression, seizure, or other effects associated with epinephrine intoxication resulting from tumor manipulation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available: Infants, Children, and Adolescents: IV: 0.05 to 0.1 mg/kg/dose (Cot&eacute; 2013). <b>Note:</b> Usual adult dose is 5 mg/dose (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse): Note:</b> Dose is based upon the number of cartridge(s) of local anesthetic administered; location and administration technique (infiltration or block injection) should be the same as used for local anesthetic administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;3 years weighing &ge;15 kg and Adolescents: Submucosal oral injection: Infiltration or block technique:</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Amount of Local Anesthetic Administered</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Dose of OraVerse</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>/<sub>4</sub> Cartridge</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup> 1</sup>/<sub>4</sub> Cartridge (0.1 mg)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>/2 Cartridge</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <sup>1</sup>/2 Cartridge (0.2 mg)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 Cartridge</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1 Cartridge (0.4 mg)</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 Cartridges</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 Cartridges (0.8 mg)</p></td></tr></tbody></table>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">15 to &lt;30 kg: 0.2 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg: 0.8 mg/dose; <b>Note:</b> A dose of &gt;0.4 mg has not been studied in children &lt;4 years</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209223\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370230\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22370231\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209199\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/mL (1 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as mesylate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OraVerse: 0.4 mg/1.7 mL (1.7 mL) [contains edetate disodium; dental cartridge]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection, as mesylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209183\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209202\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Extravasation management (treatment), sympathomimetic vasopressors: Stop vesicant infusion immediately and disconnect IV line (leave needle/cannula in place); gently aspirate extravasated solution from the IV line (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Inject small amounts of phentolamine 5 to 10 mg in 10 to 20 mL saline into extravasation site (as soon as possible but within 12 hours of extravasation). Apply dry warm compresses (Hurst 2004; Reynolds 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pheochromocytoma diagnosis: Patient should be supine throughout test, preferable in a quiet, dark room. Blood pressure should be monitored every 10 minutes for at least 30 minutes, delay phentolamine administration until after blood pressure is stable (at an untreated, hypertensive level). A drop in blood pressure &gt;35 mm Hg (systolic) and &gt;25 mm Hg (diastolic) is considered a positive response. If blood pressure is elevated, unchanged, or decrease is &lt;35 mm Hg (systolic) and &lt;25 mm Hg (diastolic), then response is negative. Confirm positive response with other diagnostic measure. Negative responses do not exclude a pheochromocytoma diagnosis, particularly in patients with paroxysmal hypertension where an incidence of false negatives is high.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: After IM injection, monitor blood pressure every 5 minutes for 35 to 40 minutes. Blood pressure drops to above parameters within 20 minutes are considered positive.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Inject rapidly (after venous response to venipuncture has subsided); then monitor blood pressure immediately after injection, every 30 seconds for 3 minutes, then every minute for 7 minutes. Maximum response is generally achieved within 2 minutes; duration may last 15 to 30 minutes (although return to prior blood pressure may be sooner).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pheochromocytoma-associated hypertensive episode: Administer IM or IV 1 to 2 hours prior to surgery and repeat during surgery (IV) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reversal of oral soft tissue (lip, tongue) anesthesia (OraVerse): Submucosal oral injection: Use the same location and dental technique employed for administration of the local anesthetic.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypertensive crisis (off-label use): Administer as an IV bolus (Marik 2007); may follow with a continuous IV infusion (McMillian 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209200\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pheochromocytoma: </b>Diagnosis of pheochromocytoma via the phentolamine-blocking test (see &quot;<b>Note</b>&quot;); prevention and management of hypertensive episodes associated with pheochromocytoma resulting from stress or manipulation during the perioperative period</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extravasation management:</b> Prevention and treatment of dermal necrosis/sloughing after extravasation of norepinephrine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Local anesthesia reversal</b> <b>(OraVerse):</b> Reversal of soft tissue (lip, tongue) anesthesia and the associated functional deficits resulting from an  intraoral submucosal injection of a local anesthetic containing a vasoconstrictor in adult and pediatric patients &ge;3 years.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> The phentolamine-blocking test for the diagnosis of pheochromocytoma has largely been supplanted by the measurement of catecholamine concentrations and catecholamine metabolites (eg, metanephrine) in the plasma and urine; reserve phentolamine for cases when additional confirmation is necessary to determine diagnosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470498\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Hypertensive crisis; Extravasation of sympathomimetic vasopressors</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209252\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Phentolamine may be confused with phentermine, Ventolin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Regitine may be confused with Reglan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209190\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Bradycardia (OraVerse 2% to 4%), hypertension (OraVerse &lt;3%), cerebrovascular occlusion, hypotension, myocardial infarction </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Mouth pain (OraVerse &le;19%), headache (OraVerse 6%), paresthesia (OraVerse &lt;3%; mild, transient), cerebrovascular spasm </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Facial swelling (OraVerse &lt;3%), pruritus (OraVerse &lt;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea (OraVerse &lt;3%), upper abdominal pain (OraVerse &lt;3%), vomiting (OraVerse &lt;3%), nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Pain at injection site (OraVerse  6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Jaw pain (OraVerse &lt;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Postinjection pain (10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing and/or case reports: Cardiac arrhythmia, dizziness, flushing, nasal congestion, orthostatic hypotension, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209205\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to phentolamine, any component of the formulation, or related compounds; MI (or history of MI), coronary insufficiency, angina, or other evidence suggestive of coronary artery disease (excluding OraVerse)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Hypotension</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209187\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular effects: MI, cerebrovascular spasm, and cerebrovascular occlusion have been reported following administration, usually associated with hypotensive episodes producing shock-like states. Tachycardia and cardiac arrhythmias may occur. Use with caution in patients with a history of cardiovascular disease. Discontinue if symptoms of angina occur or worsen. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: The use of phentolamine as a blocking agent in the screening of patients with hypertension has predominantly been replaced with urinary/biochemical assays; phentolamine use should be reserved for situations where additional confirmation is necessary and after risks associated with use have been considered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299867\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209192\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9767&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.<b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the orthostatic hypotensive effect of Alpha1-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers (Nonselective). Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilmenidine: Alpha1-Blockers may enhance the hypotensive effect of Rilmenidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209195\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13823798\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some oral animal reproduction studies. Diagnosing and treating pheochromocytoma is critical for favorable maternal and fetal outcomes (Schenker 1971; Schenker 1982). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20325560\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if phentolamine is excreted in breast milk. Due to the potential for serious adverse reaction in the nursing infant, the decision to discontinue phentolamine or discontinue breast-feeding during treatment should take in account the benefits of treatment to the mother. The manufacturer of OraVerse recommends the developmental and health benefits of breast-feeding be considered along with the mother&rsquo;s clinical need for phentolamine and any potential adverse effects on the breast-fed infant from phentolamine, or from the underlying maternal condition.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209197\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate; monitor and document extravasation site; monitor patient for orthostasis; assist patient with ambulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209186\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively blocks alpha-adrenergic receptors (nonselective) to produce brief antagonism of circulating epinephrine and norepinephrine to reduce hypertension caused by alpha effects of these catecholamines and minimizes tissue injury due to extravasation of these and other sympathomimetic vasoconstrictors (eg, dopamine, phenylephrine); also has a positive inotropic and chronotropic effect on the heart thought to be due to presynaptic alpha-2 receptor blockade which results in release of presynaptic norepinephrine (Hoffman 1980)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">OraVerse: Causes vasodilation and increased blood flow in injection area via alpha-adrenergic blockade to accelerate reversal of soft tissue anesthesia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F209204\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IM: 15 to 20 minutes; IV: 1 to 2 minutes (Chobanian 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: OraVerse: 10 to 20 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IM: 30 to 45 minutes; IV: 10 to 30 minutes (Chobanian 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 19 minutes; Submucosal injection: ~2 to 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~13% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323680\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Phentolamine Mesylate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (1): $510.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038766\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Fentanor (IN);</li>\n      <li>Oraverse (ES);</li>\n      <li>Phentolmin (KR);</li>\n      <li>Phentosol (IN, LK);</li>\n      <li>Regitin (CH, DK, HN);</li>\n      <li>Regitina (AR, BR, VE);</li>\n      <li>Regitine (BE, CN, EG, GR, HK, HU, IL, KW, LU, NL, NZ, QA, SA);</li>\n      <li>Rogitine (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Boynes SG, Riley AE, Milbee S, et al. Evaluating complications of local anesthesia administration and reversal with phentolamine mesylate in a portable pediatric dental clinic.<i> Gen Dent.</i> 2013;61(5):70-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. <i>JAMA</i>. 2003;289(19):2560-2572.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/12748199/pubmed\" target=\"_blank\" id=\"12748199\">12748199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cote CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 5th ed. Elsevier; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doellman D, Hadaway L, Bowe-Geddes LA, et al, &ldquo;Infiltration and Extravasation: Update on Prevention and Management,&rdquo; <i>J Infus Nurs</i>, 2009, 32(4):203-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/19605999/pubmed\" target=\"_blank\" id=\"19605999\">19605999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flemmer L, Chan JS. A pediatric protocol for management of extravasation injuries. <i>Pediatr Nurs. </i>1993;19(4):355-358, 424.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/8414723/pubmed\" target=\"_blank\" id=\"8414723\">8414723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill JM. Phentolamine mesylate: the antidote for vasopressor extravasation. <i>Crit Care Nurse</i>. 1991;11(10):58-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/1720079/pubmed\" target=\"_blank\" id=\"1720079\">1720079</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm. </i>1983;17(10):713-717.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/6628223/pubmed\" target=\"_blank\" id=\"6628223\">6628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17565029\"></a>Marik PE and Varon J. Hypertensive Crises: challenges and management. <i>Chest</i>. 2007;131:1949-1962.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/17565029/pubmed\" target=\"_blank\" id=\"17565029\">17565029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21200059\"></a>McMillian WD, Trombley BJ, Charash WE, et al. Phentolamine Continuous infusion in a patient with pheochromocytoma. <i>Am J Health-Syst Pharm</i>. 2011;68:130-134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/21200059/pubmed\" target=\"_blank\" id=\"21200059\">21200059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 7th ed, Philadelphia PA: Churchill Livingstone, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montgomery LA, Hanrahan K, Kottman K, et al. Guideline for I.V. infiltrations in pediatric patients. <i>Pediatr Nurs.</i> 1999;25(2):167-169, 173-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/10532013/pubmed\" target=\"_blank\" id=\"10532013\">10532013</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15931336\"></a>Myklejord DJ. Undiagnosed Pheochromocytoma: The anesthesiologist nightmare. <i>Clin Med Res</i>. 2004;2(1):59-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/15931336/pubmed\" target=\"_blank\" id=\"15931336\">15931336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    OraVerse (phentolamine mesylate) [prescribing information]. Louisville, CO: Septodont Inc; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peberdy MA, Callaway CW, Neumar RW, et al. Part 9: post cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation.</i> 2010;122(18)(suppl 3):768-786.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/20956225/pubmed\" target=\"_blank\" id=\"20956225\">20956225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phentolamine powder for solution [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; September 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24420913\"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/24420913/pubmed\" target=\"_blank\" id=\"24420913\">24420913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rhoney D and Peacock WF, &ldquo;Intravenous Therapy for Hypertensive Emergencies, Part 1&rdquo;, <i>Am J Health-Syst Pharm</i>, 2009, 66(15):1343-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/19635770/pubmed\" target=\"_blank\" id=\"19635770\">19635770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenker JG and Chowers I, &quot;Pheochromocytoma and Pregnancy. Review of 89 Cases,&quot; <i>Obstet Gynecol Surv</i>, 1971, 26(11):739-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/5173093/pubmed\" target=\"_blank\" id=\"5173093\">5173093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenker JG and Granat M, &quot;Phaeochromocytoma and Pregnancy - An Updated Appraisal,&quot; <i>Aust N Z J Obstet Gynaecol</i>, 1982, 22(1):1-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/6954937/pubmed\" target=\"_blank\" id=\"6954937\">6954937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schummer W, Schummer C, Bayer O, et al, &ldquo;Extravasation Injury in the Perioperative Setting,&rdquo; <i>Anesth Analg</i>, 2005, 100(3):722-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/15728059/pubmed\" target=\"_blank\" id=\"15728059\">15728059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14727943\"></a>Tuncel M and Ram VC, &ldquo;Hypertensive Emergencies. Etiology and Management,&rdquo; <i>Am J Cardiovasc Drugs</i>, 2003, 3(1):21-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/phentolamine-drug-information/abstract-text/14727943/pubmed\" target=\"_blank\" id=\"14727943\">14727943</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9767 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45617054\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F209218\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F209245\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F209222\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F209233\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F209223\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22370230\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22370231\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F209199\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F209183\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F209202\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F209200\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470498\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F209252\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F209190\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F209205\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F209187\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299867\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F209192\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F209195\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13823798\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20325560\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F209197\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F209186\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F209204\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323680\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038766\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9767|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=phentolamine-patient-drug-information\" class=\"drug drug_patient\">Phentolamine: Patient drug information</a></li><li><a href=\"topic.htm?path=phentolamine-pediatric-drug-information\" class=\"drug drug_pediatric\">Phentolamine: Pediatric drug information</a></li></ul></div></div>","javascript":null}